Sinopep Allsino Partners with Vazyme to Advance Synthetic Biology
China-based Jiangsu Sinopep Allsino Biopharmaceutical Co., Ltd. (SHA: 688076) announced a strategic partnership with compatriot...
Sinopep-Allsino Biopharmaceutical
Sinopep-Allsino Partners with Gulf Pharmaceutical for Semaglutide API Supply
Jiangsu-based Contract Development and Manufacturing Organization (CDMO) Sinopep-Allsino Biopharmaceutical Co., Ltd (SHA: 688076) has signed...
Sinopep-Allsino Wins NMPA Approval for Generic Liptruzet in China
Jiangsu-based CDMO Sinopep-Allsino Biopharmaceutical Co., Ltd (SHA: 688076) has received marketing approval from China’s National...
Sinopep-Allsino Bio Pharmaceutical Cuts Fundraising Target to RMB434 Million via Convertible Bonds”
Jiangsu-based Contract Development and Manufacturing Organization (CDMO) Sinopep-Allsino Biopharmaceutical Co., Ltd has revised its proposal...
Hybio Pharmaceutical’s Semaglutide API Receives FDA Review Acceptance
China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) has announced that the US Food and Drug...
Sinopep-Allsino Biopharm’s SPN0103-009 Receives NMPA Approval for Diabetes and Obesity Clinical Study
China-based Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd announced that it has received approval from the National...